CUO246 (CUO-246) is a potent, selective bacterial DNA gyrase/topoisomerase IV inhibitor, CUO246 is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens.

D66 is a specific small molecule that disrupts S. Typhimurium membrane voltage without cell lysis, prevents S. Typhimurium survival in macrophages (IC50=6.0 uM) and inhibits bacterial growth under conditions that compromise the cell envelope.

DS01750413 is a novel FtsZ inhibitor and new derivative of PC190723 (Cat. PC-47012), inhibits S. aureus FtsZ protein with IC50 of 2 mg/L, has an IC50 of 0.03 mg/L in cell elongation assay of B. subtilis.

EPM35 (Efflux pump modulator 35) is a small molecule that bind AcrB (KD=0.29 uM), inhibit AcrAB-TolC and modulates bacterial efflux pump activity, reduces bacterial intracellular load.

GSK030 (GSK3212030A) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites.

GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM).

GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM).

HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors.

HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL.

IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL).

JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation.

JMV7061 (JMV-7061) is a novel potent, selective bacterial metallo-β-lactamase (MBL) inhibitor, shows submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition (Ki=10-30 nM).

JSF-2414 (JSF2414) is a potent, small molecule GyrB/ParE dual binding inhibitor, simultaneously binds to ATP binding regions of DNA gyrase (GyrB) and topoisomerase (ParE) and displays potent in vitro activity against strains of MRSA, VRSA and VISA.

JSF-2659 is the orally bioavailable, phosphate prodrug of JSF-2414, JSF-2659 (100 and 1 g/kg, p.o.) is highly efficacious in reducing microbial burdens in animal models of Neisseria gonorrhoeae vaginal infection as well as VRSA and C. difficile-induced co

JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM.

JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM.

KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity.

KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene.

LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities.

MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics.

MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM.

MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively.